50 likes | 263 Views
Nt-proBNP and 5-years survival in a large cohort of type 2 diabetes: the Casale Monferrato Study. M. Perotto , F. Panero, A. Landi, S. Miglietta, F. Monasterolo, P. Cavallo Perin, G. Bruno Department of Internal Medicine, University of Turin, Italy. M. G. S. D. 28/04 - 01/05/2011.
E N D
Nt-proBNP and 5-years survival in a large cohort of type 2 diabetes: the Casale Monferrato Study. M. Perotto, F. Panero, A. Landi, S. Miglietta, F. Monasterolo, P. Cavallo Perin, G. BrunoDepartment of Internal Medicine, University of Turin, Italy.M. G. S. D. 28/04 - 01/05/2011
Mortality to 5 years Years of diabetes sex age eGFR NT – pro BNP AER HbA1c hypertension CVD ApoB ApoA1 smoking
The Casale Monferrato Study Resident in Casale Monferrato 2381 patients Diabetes mellitus type 2 Randomized extraction 666 patients Identified by: • Paper archive of the patients attending the diabetes service at the Santo Spirito Hospital in Casale Monferrato • Centralized file of all patients who have obtained exemption from payment for drugs, syringes, and glucose-monitoring strips owning to a diagnosis of diabetes
NT-proBNP N death rate/1000person/yr IC 95% 0 – 48 14 15.0 8.89 – 25.36 49 – 102 24 27.1 18.16 – 40.43 103 – 232 38 46.9 34.13 – 64.46 > 233 80 107.0 85.9 – 133.22 NT-proBNP N death rate/1000person/yr IC 95% 0 – 48 3 3.2 1.04 – 9.98 49 – 102 9 10.2 5.28 – 19.53 103 – 232 22 27.2 17.88 – 41.24 > 233 38 50.8 39.98 – 69.25 All causes mortality CV mortality
mortality all causes CV mortality HRs Model 1 HRs Model 2 HRs Model 1 HRs Model 2 NT-proBNP 0 – 48 1.00 1.00 1.00 1.00 49 – 102 1.41 (0.72 – 2.75) 3.62 (0.94 – 13.9) 2.50 (0.67 – 9.33) 2.11 (0.18 – 24.87) 103 – 232 2.14 (1.13 – 4.06) 3.88 (1.01 – 14.86) 5.92 (1.72 – 20.38) 6.88 (0.74 – 63.64) > 233 4.42 (2.41 – 8.08) 8.96 (2.35 – 34.17) 10.03 (2.97 – 33.85) 8.07 (0.88 – 73.48) P for trend <0.0001 0.011 <0.0001 <0.001 Cox Multivariate Analysis Diabetologia. 2006 Oct;49(10):2256-62. Epub 2006 Aug 26. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. L. Tarnow, M.-A. Gall, B. V. Hansen, P. Hovindand H.-H. Parving